Patient Characteristics | ALL patients(Number (percent)) |
---|---|
Total no. of patients | 30 (100) |
Median age, years (range) | 55 (26–74) |
Sex | |
Female | 8 (27) |
Male | 22 (73) |
Metastatic stage (n) | |
M0 | 1 (3) |
M1a | 6 (20) |
M1b | 6 (20) |
M1c | 17 (57) |
Lactate dehydrogenase | |
≤ ULNa | 20 (67) |
> ULN | 10 (33) |
ECOG | |
0 | 19 (63) |
1 | 11 (37) |
Primary site | |
Cutaneous | 24 (80) |
Mucosal | 2 (7) |
Ocular | 3 (10) |
Unknown primary | 1 (3) |
BRAF status | |
BRAF mutated (V600E) | 9 (30) |
BRAF wild type | 21 (70) |
Prior therapies** | |
Prior adjuvant therapy | 5 (17) |
Prior therapy with a BRAF inhibitor | 6 (20) |
Brain metastases | |
Patients without brain metastases | 26 (87) |
Patients with brain metastases | 4 (13) |
aULN denotes upper limit of the normal, ** One patient (3%) received 2 weeks a of Temozolomide